552,367 Shares in Marsh & McLennan Companies, Inc. $MRSH Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Marsh & McLennan Companies, Inc. (NYSE:MRSH) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 552,367 shares of the financial services provider’s stock, valued at approximately $102,475,000. Healthcare of Ontario Pension Plan Trust Fund owned 0.11% of Marsh & McLennan Companies at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRSH. Numerai GP LLC grew its holdings in Marsh & McLennan Companies by 966.2% in the third quarter. Numerai GP LLC now owns 37,220 shares of the financial services provider’s stock valued at $7,501,000 after purchasing an additional 33,729 shares during the last quarter. Swiss Life Asset Management Ltd grew its holdings in Marsh & McLennan Companies by 9.5% in the fourth quarter. Swiss Life Asset Management Ltd now owns 134,542 shares of the financial services provider’s stock valued at $24,960,000 after purchasing an additional 11,648 shares during the last quarter. Barclays PLC grew its holdings in Marsh & McLennan Companies by 41.7% in the third quarter. Barclays PLC now owns 2,202,372 shares of the financial services provider’s stock valued at $443,844,000 after purchasing an additional 647,987 shares during the last quarter. Sarasin & Partners LLP grew its holdings in Marsh & McLennan Companies by 0.9% in the fourth quarter. Sarasin & Partners LLP now owns 934,732 shares of the financial services provider’s stock valued at $173,411,000 after purchasing an additional 8,283 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in Marsh & McLennan Companies by 26.4% in the third quarter. Brown Brothers Harriman & Co. now owns 136,179 shares of the financial services provider’s stock valued at $27,444,000 after purchasing an additional 28,419 shares during the last quarter. Institutional investors and hedge funds own 87.99% of the company’s stock.

Marsh & McLennan Companies Trading Up 0.3%

NYSE MRSH opened at $168.67 on Friday. Marsh & McLennan Companies, Inc. has a twelve month low of $156.60 and a twelve month high of $220.32. The stock has a market cap of $81.49 billion, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 2.46 and a beta of 0.62. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 1.28.

Marsh & McLennan Companies (NYSE:MRSH) last released its quarterly earnings data on Thursday, April 16th. The financial services provider reported $3.29 EPS for the quarter, topping analysts’ consensus estimates of $3.21 by $0.08. The company had revenue of $7.30 billion for the quarter. Marsh & McLennan Companies had a return on equity of 31.87% and a net margin of 14.26%.The business’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, research analysts anticipate that Marsh & McLennan Companies, Inc. will post 10.38 earnings per share for the current year.

Insider Activity

In other news, CEO John Q. Doyle sold 16,656 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $161.71, for a total value of $2,693,441.76. Following the completion of the sale, the chief executive officer owned 116,811 shares in the company, valued at approximately $18,889,506.81. This trade represents a 12.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRSH. Bank of America lowered their target price on Marsh & McLennan Companies from $181.00 to $174.00 and set an “underperform” rating on the stock in a report on Tuesday, April 14th. Morgan Stanley reduced their price objective on Marsh & McLennan Companies from $195.00 to $190.00 and set an “equal weight” rating on the stock in a research report on Monday, April 6th. Raymond James Financial upgraded Marsh & McLennan Companies from an “outperform” rating to a “strong-buy” rating and set a $225.00 price objective on the stock in a research report on Tuesday, February 17th. Citigroup upgraded Marsh & McLennan Companies from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Wednesday, May 6th. Finally, Barclays reduced their price objective on Marsh & McLennan Companies from $209.00 to $206.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Marsh & McLennan Companies presently has an average rating of “Hold” and a consensus target price of $200.19.

Marsh & McLennan Companies Profile

Marsh & McLennan Companies (NYSE: MMC) is a global professional services firm headquartered in New York City that provides advice and solutions in the areas of risk, strategy and people. Founded in 1905, the company has grown into a diversified group of businesses focused on insurance brokerage and risk management, reinsurance, human capital and investment consulting, and management consulting. Its long history and scale position it as a prominent adviser to corporations, governments and other institutions seeking to manage risk and optimize human and financial capital.

The firm operates through several well-known subsidiaries and business units that specialize in distinct services.